N_N20R1 Cell Line

Please Enter Your Email ID
Email ID

Cat. #152840

N_N20R1 Cell Line

Cat. #: 152840

Sub-type: Continuous

Unit size: 1x10^6 cells / vial

Availability: 3-4 weeks

Organism: Human

Tissue: Lung

Disease: Cancer

Model: Cancer Model


This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.


Inventor: John Lunec

Institute: Newcastle University

Tool Details

Tool Details


  • Name: N_N20R1 Cell Line
  • Cancer: Neurological cancer
  • Cancers detailed: Neuroblastoma
  • Research fields: Apoptosis and autophagy;Cancer;Cell biology;Drug development;Genetics
  • Tool sub type: Continuous
  • Parental cell: NGP
  • Organism: Human
  • Tissue: Lung
  • Disease: Cancer
  • Model: Cancer Model
  • Conditional: No
  • Description: To determine how resistance to MDM2/p53 binding antagonists might develop, NGP cells were exposed to growth inhibitory concentrations of a MDM2 inhibitor, Nutlin-3, and a clonal resistant cell line was generated. The p53 mediated responses of the parental and resistant cell line were compared. In contrast to the parental cell lines, p53 activation by Nutlin-3, MI-63 or ionizing radiation was not observed in the NGP derived cell line, N_N20R1.
  • Production details: Resistant cell lines were established by exposing NGP cells to Nutlin-3. Single cell derived colonies were isolated with cloning cylinders and the clonal population expanded in culture medium containing the MDM2/p53 antagonist refreshed weekly for 60 days. Stage 1 resistant clones were then further exposed to increased concentrations of Nutlin-3 for 30 days to generate stage 2 resistant clones.
  • Biosafety level: 1


  • Format: Frozen
  • Unit size: 1x10^6 cells / vial
  • Shipping conditions: Dry ice
  • Storage conditions: Liquid Nitrogen
  • Mycoplasma free: Yes


  • TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation.
  • Drummond et al. 2016. Oncotarget. :. PMID: 27323823.